Pre-clinical studies for Liver Cancer: STAM model
For Today’s topic, I would like to focus on Hepatocellular Carcinoma (HCC).
We have summarized the characteristics of the various liver cancer models, and you can learn more about them by clicking on the link below.
If you are interested in learning about how to prevent and treat liver cancer, please read on.
KEYWORD：Hepatocellular Carcinoma, Liver Cancer
Liver cancer is the 3rd leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) alone accounts for 90% of these cases.
Therefore, developing a treatment for HCC is imperative, as finding a cure for HCC will save the lives of thousands of cancer patients.
With that in mind, I would like to introduce our proprietary NASH-HCC model (STAM™) for the development of therapeutic agents for HCC.
The STAM™ was originally developed as a NASH model, but with a 100% occurrence of hepatocellular carcinoma(HCC) as early as 20 weeks of age, it is also an excellent platform for oncology research and therapeutic development.
Please find the comparison table of STAM™ and other HCC models below.
We believe that a pharmacological study using this model could help you progress with the research and development of your compound.
We have conducted many drug efficacy evaluation studies for HCC as well as published many publications. Please feel free to contact us if you have any questions, including our past experience.